This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (7)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in this journal  Topic Collections  • Viral Infections  • Neurology  • Neurology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

A 14-Year Follow-up Study

Stéphane Olindo, MD; Philippe Cabre, MD; Agnes Lézin, PhD; Harold Merle, MD; Martine Saint-Vil, MD; Aissatou Signate, MD; Mickael Bonnan, MD; Aurelie Chalon, PhD; Lionel Magnani, MD; Raymond Cesaire, MD, PhD; Didier Smadja, MD

Arch Neurol. 2006;63:1560-1566.

Background  The progression of neurological disability in human T-lymphotropic virus 1 (HTLV-1)–associated myelopathy/tropical spastic paraparesis (HAM/TSP) remains undefined.

Objectives  To determine the time course of disability scores and to identify predictors of outcome among patients with HAM/TSP.

Design  Clinical 14-year follow-up study.

Setting  University hospital.

Patients  One hundred twenty-three patients with HAM/TSP.

Main Outcome Measures  We determined time from onset to the following 4 Kurtzke Disability Status Scale (DSS) end points: scores of 6 (unilateral aid required), 6.5 (bilateral aid required), 8 (wheelchair confinement), and 10 (death related to the disease). Times to reach selected DSS scores were estimated using the Kaplan-Meier method. Univariate and multivariate analyses identified variables related to the rate of progression to DSS 8. The HTLV-1 proviral loads were also assessed.

Results  The disability of the cohort progressed throughout the follow-up period. The median times from onset to DSS 6, 6.5, and 8 were 6, 13, and 21 years, respectively. The median time from DSS 6 to DSS 8 was 8 years; DSS 10 was reached by one fourth of the patients within 20 years. Age at onset of 50 years or older and high HTLV-1 proviral load were associated with a shorter time to DSS 8 (P = .01 and P = .02, respectively). A shorter time to DSS 6 significantly adversely affected the time to progression from DSS 6 to DSS 8.

Conclusions  Human T-lymphotropic virus 1–associated myelopathy/tropical spastic paraparesis is a rapidly disabling disease. Monitoring for HTLV-1 proviral load is recommended in future therapeutic trials.

Author Affiliations: Departments of Neurology (Drs Olindo, Cabre, Saint-Vil, Signate, Bonnan, and Smadja), Viro-Immunology (Drs Lézin, Chalon, and Cesaire), Ophthalmology (Dr Merle), and Statistics (Dr Magnani), University Hospital of Fort de France, Fort de France, Martinique.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Other Important Aspects of Human T-Lymphotropic Virus 1–Associated Myelopathy
Marco A. Lima, Ana C. Leite, Marcus T. Silva, and Abelardo Q. Araújo
Arch Neurol. 2007;64(7):1059.
EXTRACT | FULL TEXT  

Other Important Aspects of Human T-Lymphotropic Virus 1–Associated Myelopathy—Reply
Stéphane Olindo, Agnès Lézin, and Didier Smadja
Arch Neurol. 2007;64(7):1059-1060.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The neurology of HTLV-1 infection
Cooper et al.
PN 2009;9:16-26.
ABSTRACT | FULL TEXT  

Neurological morbidity among human T-lymphotropic-virus-type-1-infected individuals in a rural West African population
Cooper et al.
J. Neurol. Neurosurg. Psychiatry 2009;80:66-68.
ABSTRACT | FULL TEXT  

Other Important Aspects of Human T-Lymphotropic Virus 1-Associated Myelopathy
Lima et al.
Arch Neurol 2007;64:1059-1059.
FULL TEXT  

Other Important Aspects of Human T-Lymphotropic Virus 1-Associated Myelopathy--Reply
Olindo et al.
Arch Neurol 2007;64:1059-1060.
FULL TEXT